source
- Novo Nordisk shares slide 6% after Wegovy pill sales miss despite earnings beatNovo Nordisk reported second‑quarter results that beat both revenue and profit forecasts, posting a profit of $5.15 billion. The company’s oral Wegovy obesity pill generated $496 million in sales,…
- Vertex posts strong Q2 earnings, but upcoming Sionna cystic fibrosis data casts a shadowVertex reported Q2 revenue from its cystic fibrosis portfolio exceeding $3.2 billion, beating estimates and prompting an upward revision of full‑year revenue guidance to $13.1‑$13.2 billion. Analy…